STUDY OF SGN-40 (ANTI-HUCD40 MAB) IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。假设：这项针对非霍奇金淋巴瘤（NHL）患者的I期研究的目标是：1。确定每周4次剂量的抗人CD40单克隆抗体sgn - 402的安全性。确定每周4次sgn3的最大耐受剂量。目的：NHL是一种起源于淋巴细胞的异质性恶性肿瘤。在美国，发病率估计约为54,000/年，患病率约为331,000。大多数（80%）淋巴瘤病例是b细胞起源的。虽然该疾病可发生于所有年龄段，但发病率随着年龄的增长而增加，通常始于40岁以上的成年人。NHL的特点是淋巴细胞的克隆性增殖，在淋巴结、血液、骨髓和脾脏中积累，尽管任何主要器官都可能受累。NHL可分为两种预后组：惰性组和侵袭组。强化联合化疗方案治愈了一些侵袭性非霍奇金淋巴瘤。影响近一半NHL患者的更惰性和滤泡型的疾病被认为是无法治愈的。虽然惰性NHL对放射治疗和化疗有反应，但在晚期通常会出现持续的复发率。对于初次治疗后复发且不适合干细胞移植的患者，需要能够提供临床益处的新疗法。肿瘤坏死因子（TNF）超家族成员CD40在侵袭性NHL上的表达使该抗原成为治疗复发患者的一个有吸引力的靶点。CD40是所有成熟B细胞（B淋巴细胞）、大多数B细胞恶性肿瘤、单核细胞、树突状细胞（神经系统）、内皮细胞（血管内）和上皮细胞表面的受体分子。终点：这是一项I期研究，终点将包括：确定NHL患者每周4次剂量SGN-40的安全性[剂量限制毒性（DLT）]；确定NHL患者每周4次剂量SGN-40的最大耐受剂量（MTD）；获得NHL患者SGN-40的初步抗肿瘤活性

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Hypothesis: The objectives of this Phase I study with patients with non-Hodgkin's lymphoma (NHL) are: 1. To define the safety profile of 4 weekly doses of an anti-human CD40 monoclonal antibody, SGN-40 2. To determine the maximum tolerated dose of 4 weekly doses of SGN 3. To obtain preliminary anti-tumor activity of SGN-40 Goals: NHL is a heterogeneous malignancy originating from lymphocytes. In the United States, the incidence is estimated at about 54,000/year with a prevalence of approximately 331,000. The majority (80%) of lymphoma cases is of B-cell origin. While the disease can occur in all ages, the incidence increases with age, with the usual onset beginning in adults over 40 years. NHL is characterized by a clonal proliferation of lymphocytes that accumulate in the lymph nodes, blood, bone marrow, and spleen, although any major organ may be involved. NHL can be divided into two prognostic groups: indolent and aggressive. Intensive combination chemotherapy regimens cure some cases of the aggressive forms of NHL. The more indolent and follicular forms of the disease that affect nearly half of all patients with NHL are considered incurable. While indolent NHL is responsive to radiation therapy and chemotherapy, a continuous rate of relapse is usually seen in advanced stages. In patients who have relapsed from primary treatment and who are not candidates for stem cell transplantation, novel therapies that can provide clinical benefit are needed. The expression of CD40, a member of the tumor necrosis factor (TNF) superfamily, on aggressive NHL makes this antigen an attractive target for treatment of relapsed patients. CD40 is a receptor molecule on the cell surface of all mature B cells (B lymphocytes), most B-cell malignancies, monocytes, dendritic cells (in the nervous system), endothelial cells (within blood vessels), and epithelial cells. Endpoints: This is a Phase I study, and as such endpoints will include: ¿ Defining the safety profile [dose limiting toxicity (DLT)] of 4 weekly doses of SGN-40 in patients with NHL ¿ Determining the maximum tolerated dose (MTD) of 4 weekly doses of SGN-40 in patients with NHL ¿ Obtaining preliminary anti-tumor activity of SGN-40 in patients with NHL